KFRX 04
Alternative Names: KFRX-04Latest Information Update: 22 Sep 2023
At a glance
- Originator KeifeRx
- Class Antidementias; Antineoplastics; Skin disorder therapies
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Mastocytosis; Mild cognitive impairment; Urticaria
Most Recent Events
- 29 Mar 2023 Preclinical trials in Mastocytosis in USA (PO) (keiferx pipeline, March 2023)
- 29 Mar 2023 Preclinical trials in Mild cognitive impairment in USA (PO) (keiferx pipeline, March 2023)
- 29 Mar 2023 Preclinical trials in Urticaria in USA (PO) (keiferx pipeline, March 2023)